Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Virios Therapeutics (Nasdaq: VIRI), a development-stage biotech company, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, before the financial markets open. The company specializes in developing novel antiviral therapies for chronic conditions such as fibromyalgia and Long-COVID. This upcoming financial report will provide insights into Virios Therapeutics' financial performance and potentially its progress in advancing its therapeutic pipeline for these debilitating chronic diseases.
Virios Therapeutics (Nasdaq: VIRI), una società biotech in fase di sviluppo, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 giovedì 8 agosto 2024, prima dell'apertura dei mercati finanziari. L'azienda è specializzata nello sviluppo di nuove terapie antivirali per condizioni croniche come fibromialgia e Long-COVID. Questo prossimo rapporto finanziario fornirà informazioni sulle performance finanziarie di Virios Therapeutics e potenzialmente sul progresso nella valorizzazione della sua pipeline terapeutica per queste malattie croniche debilitanti.
Virios Therapeutics (Nasdaq: VIRI), una empresa biotecnológica en etapa de desarrollo, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto de 2024, antes de la apertura de los mercados financieros. La compañía se especializa en desarrollar nuevas terapias antivirales para condiciones crónicas como fibromialgia y Long-COVID. Este próximo informe financiero proporcionará información sobre el desempeño financiero de Virios Therapeutics y posiblemente su avance en la mejora de su cartera de terapias para estas enfermedades crónicas debilitantes.
Virios Therapeutics (Nasdaq: VIRI), 개발 단계의 생명공학 회사는 2024년 2분기 재무 결과를 2024년 8월 8일 목요일에 금융 시장 개장 전에 발표할 예정이라고 밝혔습니다. 이 회사는 섬유근육통 및 롱코비드와 같은 만성 질환을 위한 신규 항바이러스 치료제 개발에 전문화되어 있습니다. 이번 재무 보고서는 Virios Therapeutics의 재무 성과 및 이러한 만성 질병에 대한 치료 파이프라인의 진행 상황에 대한 통찰력을 제공할 것입니다.
Virios Therapeutics (Nasdaq: VIRI), une entreprise biopharmaceutique en phase de développement, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le jeudi 8 août 2024, avant l'ouverture des marchés financiers. L'entreprise se spécialise dans le développement de nouvelles thérapies antivirales pour des conditions chroniques telles que la fibromyalgie et le Long-COVID. Ce prochain rapport financier fournira des informations sur la performance financière de Virios Therapeutics et potentiellement sur l'avancement de son pipeline thérapeutique pour ces maladies chroniques débilitantes.
Virios Therapeutics (Nasdaq: VIRI), ein Biotech-Unternehmen in der Entwicklungsphase, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am Donnerstag, den 8. August 2024, vor der Eröffnung der Finanzmärkte veröffentlichen wird. Das Unternehmen hat sich auf die Entwicklung von neuen antiviralen Therapien für chronische Erkrankungen wie Fibromyalgie und Long-COVID spezialisiert. Dieser bevorstehende Finanzbericht wird Einblicke in die finanzielle Leistung von Virios Therapeutics und möglicherweise in den Fortschritt seiner therapeutischen Pipeline für diese belastenden chronischen Erkrankungen geben.
- None.
- None.
ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets.
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system. The Company’s lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dosage combination of famciclovir and celecoxib) has been granted fast track designation by the FDA.
For more information, please visit www.virios.com.
Follow Virios Therapeutics
Email Alerts: https://ir.virios.com/resources/email-alerts
LinkedIn: https://www.linkedin.com/company/viriosbiotech/
Twitter: https://twitter.com/ViriosBiotech
Facebook: https://www.facebook.com/ViriosBiotech/
Forward-Looking Statements
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Virios Therapeutics’ product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. undertakes no duty to update such information except as required under applicable law.
Contact:
FAQ
When will Virios Therapeutics (VIRI) report its Q2 2024 financial results?
What is the focus of Virios Therapeutics (VIRI)?
What is the stock symbol for Virios Therapeutics?
What diseases does Virios Therapeutics (VIRI) aim to treat?
